← Leaderboards
Jessica Scott
Sloan-Kettering Inst Can Research
$10,593,887
Attributed
$13,062,727
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,062,727 · 3
By mechanism
U01$4,937,681 · 1
R01$4,082,444 · 1
R37$4,042,602 · 1
Top collaborators
- Andrea Cercek6 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Andrea Cercek$4,410,417
- Richard N Kolesnick$17,601,323
- Maria E Arcila$896,260
- Michael H. A. Roehrl$6,530,724
- Sarat Chandarlapaty$10,852,142
Others in their field
Other Emerging Leaders on “Malignant Breast Neoplasm”
- Greg Yothers · University Of Chicago$35,003,821
- Olwen Hahn · Brigham And Women'S Hospital$32,076,706
- Leonard Freedman · Leidos Biomedical Research, Inc.$21,750,066
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Leonard Freedmand · Leidos Biomedical Research, Inc.$12,635,631
- Christoph I Lee · University Of Washington$9,283,572
Research focus
Malignant Breast NeoplasmCommon Terminology Criteria For Adverse EventsPatient Outcomes AssessmentsDoseRandomized TrialInvestigationPrimary EndpointRegimenResponseTreadmillOncologySafetyMalignant NeoplasmsAerobic ExerciseQuality Of LifeExercise TherapyExerciseCancer TherapyEvaluationEventQualifyingCancer CarePhase Ii/Iii TrialDiagnosis
Grant awards (17)
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial$1,442,297
R01 · FY2025 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,224,361
U01 · FY2025 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$649,419
R37 · FY2025 · CA · contact PI
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial$509,999
R01 · FY2025 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,101,776
U01 · FY2024 · CA · contact PI
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial$686,954
R01 · FY2024 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$620,371
R37 · FY2024 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$11,312
U01 · FY2024 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,246,572
U01 · FY2023 · CA · contact PI
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial$708,646
R01 · FY2023 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$687,076
R37 · FY2023 · CA · contact PI
Diversity Supplement: Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$69,382
U01 · FY2023 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,284,278
U01 · FY2022 · CA · contact PI
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial$734,548
R01 · FY2022 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$701,097
R37 · FY2022 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$701,097
R37 · FY2021 · CA · contact PI
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer$683,542
R37 · FY2020 · CA · contact PI